The Medical Imaging & Technology Alliance (MITA) recently stated that the assertion in a recent comment letter filed with the IRS that the US excise tax on medical devices would provide a “windfall” for medical device companies is inaccurate and misunderstands the operation of excise taxes.
“Only in Washington could paying a $30 billion tax over the next 10 years be viewed as a windfall opportunity, but that’s exactly the false claim being made,” said Gail Rodriguez, MITA’s executive director. “MITA continues to oppose the device tax precisely because we believe it creates strong headwinds against an important sector of the US economy.”
Set to take effect in 2013, the 2.3% tax will be levied on the sale of medical devices, including medical imaging technology used to diagnose disease and stage treatment options. For companies working to maintain America’s global leadership in the development of innovative medical technologies, the medical device tax poses more challenges for manufactures, job creation and access to innovative diagnostics and therapies.
